ZP9830 phase 1 results show a clean safety run for the Zealand Kv1 3 blocker

The ZP9830 phase 1 results are in for the multiple dose part of the first human trial. Zealand Pharma said on 19 October 2026 that its Kv1.3 ion channel blocker was well tolerated over four weeks in healthy volunteers, with no serious or severe side effects. It is a safety readout, not an efficacy one, and the molecule stays in phase 1 on our board.

What the trial measured

The study is a first in human, single centre, randomized, double blind and placebo controlled phase 1 trial registered as NCT06682975 on ClinicalTrials.gov. It combines a single ascending dose part with a multiple ascending dose part. The new results cover the second part, which enrolled 32 healthy men and women. Each received repeated doses of ZP9830 or placebo, given under the skin, for four weeks, with safety follow up until day 41. The main goals were safety, tolerability and pharmacokinetics, meaning how the drug is absorbed and cleared. Proof of mechanism was an exploratory aim only. The earlier single dose part also tested one dose given into a vein and used a pharmacological model to check that the drug affects immune cells as intended.

Zealand reported no dose limiting safety findings and no other significant safety concerns. Every treatment emergent adverse event in people on ZP9830 was mild and non serious. The company saw no clinically relevant changes in vital signs, heart tracings on a 12 lead electrocardiogram, physical examinations or safety blood tests. It said the pharmacokinetic profile supports trials of longer duration but released no exposure numbers, half life or immune readouts from this part. That leaves outside readers with a qualitative summary. Without the data, it is not possible to judge how often the drug would need to be given or how strongly it engages its target in people.

Why this ion channel is an attractive target

Kv1.3 is a potassium channel on the surface of immune cells. Zealand describes it as selectively increased on effector memory T cells, a type of white blood cell that drives chronic inflammation in autoimmune disease by releasing inflammatory signals. Blocking the channel is meant to calm those cells while leaving most of the immune system intact. That is the core of the pitch. Many current treatments for autoimmune disease suppress immunity broadly and raise infection risk. A drug that hits only the overactive memory cells could, in theory, be safer. Zealand says anti inflammatory effects have been shown in preclinical models, but no human efficacy data exist yet.

A drug that hits only the overactive memory cells could, in theory, be safer.

ZP9830 belongs on a peptide tracker because of how it was made. Zealand's own investor materials list it under designed novel peptide modalities, and the company has spent more than 25 years on peptide research and development. Whether its design delivers the selectivity and exposure the target needs is the key open question, and the company has not yet shown data on either. For now, ZP9830 is one of the newer entries among immune peptide molecules, a class that so far holds mostly complement blockers and receptor antagonists. The ZP9830 phase 1 results are the first multi dose human data for it.

Where Zealand takes it next

The company has already moved into patients. Zealand said it has started a phase 1b trial in people with plaque psoriasis that includes efficacy endpoints, launched after positive single dose results earlier this year. It also plans a phase 2 trial in another autoimmune disease in the first half of 2027, without naming the disease. David Kendall, Zealand's chief medical officer, called the findings "an encouraging milestone for ZP9830" and said the data "give us the confidence to expand the development program and explore an additional autoimmune disease in 2027." The psoriasis study is the first test of whether blocking Kv1.3 actually reduces disease activity in people, and it is the next real checkpoint.

This program sits well outside Zealand's main commercial focus today. The company describes itself as centred on obesity and metabolic health, where its petrelintide partnership with Roche and its survodutide partnership with Boehringer Ingelheim draw most investor attention. Its gut work has also had setbacks, including the US rejection we covered when the FDA turned back glepaglutide in 2024. An immunology asset gives Zealand a second leg beyond metabolism, but early inflammation programs fail often, and safety in healthy volunteers says little about benefit. Psoriasis is also a crowded field, with injected antibodies and now oral options such as icotrokinra already approved.

How much weight to give this readout

Phase 1 safety results are the smallest step on our board. They show a drug can be given repeatedly without obvious harm in a small, healthy group over a short period. They do not show that it works, and rare or delayed side effects cannot be seen in 32 people over six weeks. Our note on stage moves explains why we treat early safety data as a modest signal. The lack of published pharmacokinetic numbers also limits what can be concluded. Until Zealand presents the data at a meeting or in a paper, investors and clinicians are relying on a company summary.

There is still meaning in a clean result. Ion channel drugs can affect other channels with similar structure, including channels in the heart and nerves. The absence of relevant changes on electrocardiograms and safety tests is therefore a necessary first hurdle for this class, even if it is not a sufficient one. It allowed Zealand to move into patients without a safety pause. The psoriasis trial will show whether target engagement translates into clinical change, and the choice of disease for the planned phase 2 study will say where Zealand sees the best fit. Until then, the ZP9830 phase 1 results are best read as permission to keep going.

Conclusion

The ZP9830 phase 1 results show a clean four week safety profile in 32 healthy volunteers, with no serious side effects and no published exposure data. The molecule stays in phase 1. The checkpoints are the psoriasis phase 1b readout and the start of a phase 2 trial in 2027.